195 related articles for article (PubMed ID: 21885990)
21. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function.
Pirro M; Schillaci G; Romagno PF; Mannarino MR; Bagaglia F; Razzi R; Pasqualini L; Vaudo G; Mannarino E
J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):14-21. PubMed ID: 19158317
[TBL] [Abstract][Full Text] [Related]
22. Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension.
Matsuo S; Saiki Y; Adachi O; Kawamoto S; Fukushige S; Horii A; Saiki Y
J Thorac Cardiovasc Surg; 2015 Mar; 149(3):902-9. PubMed ID: 25454916
[TBL] [Abstract][Full Text] [Related]
23. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
24. Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study.
Tousoulis D; Koniari K; Antoniades C; Miliou A; Noutsou M; Nikolopoulou A; Papageorgiou N; Marinou K; Stefanadi E; Stefanadis C
Clin Ther; 2010 Sep; 32(10):1720-8. PubMed ID: 21194594
[TBL] [Abstract][Full Text] [Related]
25. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
26. Single high dose atorvastatin does not ameliorate endothelial function and large arterial stiffness in dyslipidemic patients without atherosclerosis.
Tulmac M; Simşek V; Tireli E; Sahin O; Yildirim N; Doğru MT; Ebinç H
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):824-8. PubMed ID: 22913216
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression.
Tabuchi T; Satoh M; Itoh T; Nakamura M
Clin Sci (Lond); 2012 Aug; 123(3):161-71. PubMed ID: 22364258
[TBL] [Abstract][Full Text] [Related]
28. Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg.
Brunetti ND; Maulucci G; Casavecchia GP; Distaso C; De Gennaro L; Pellegrino PL; Di Biase M
J Interv Cardiol; 2007 Dec; 20(6):481-7. PubMed ID: 18042053
[TBL] [Abstract][Full Text] [Related]
29. Additive effect of homocysteine- and cholesterol-lowering therapy on endothelium-dependent vasodilation in patients with cardiovascular disease.
Wustmann K; Klaey M; Burow A; Shaw SG; Hess OM; Allemann Y
Cardiovasc Ther; 2012 Oct; 30(5):277-86. PubMed ID: 21884007
[TBL] [Abstract][Full Text] [Related]
30. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein.
Beckman JA; Liao JK; Hurley S; Garrett LA; Chui D; Mitra D; Creager MA
Circ Res; 2004 Jul; 95(2):217-23. PubMed ID: 15178637
[TBL] [Abstract][Full Text] [Related]
31. Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Meijer P; Oyen WJ; Dekker D; van den Broek PH; Wouters CW; Boerman OC; Scheffer GJ; Smits P; Rongen GA
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):963-8. PubMed ID: 19359665
[TBL] [Abstract][Full Text] [Related]
32. Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH).
ter Avest E; Abbink EJ; Holewijn S; de Graaf J; Tack CJ; Stalenhoef AF
Curr Med Res Opin; 2005 Sep; 21(9):1469-76. PubMed ID: 16197666
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study.
Lablanche JM; Leone A; Merkely B; Morais J; Alonso J; Santini M; Eha J; Demil N; Licour M; Tardif JC;
Arch Cardiovasc Dis; 2010 Mar; 103(3):160-9. PubMed ID: 20417447
[TBL] [Abstract][Full Text] [Related]
34. Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients.
Oikonomou E; Siasos G; Zaromitidou M; Hatzis G; Mourouzis K; Chrysohoou C; Zisimos K; Mazaris S; Tourikis P; Athanasiou D; Stefanadis C; Papavassiliou AG; Tousoulis D
Atherosclerosis; 2015 Feb; 238(2):159-64. PubMed ID: 25525743
[TBL] [Abstract][Full Text] [Related]
35. Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients.
Egede R; Jensen LO; Hansen HS; Antonsen L; Hansen KN; Junker A; Thayssen P
Int J Cardiol; 2012 Jul; 158(3):376-9. PubMed ID: 21349594
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the efficacy of different statins in murine collagen-induced arthritis.
Palmer G; Chobaz V; Talabot-Ayer D; Taylor S; So A; Gabay C; Busso N
Arthritis Rheum; 2004 Dec; 50(12):4051-9. PubMed ID: 15593180
[TBL] [Abstract][Full Text] [Related]
37. Statin, the black box.
Hatem S; Boccara F
Arch Cardiovasc Dis; 2008 Jun; 101(6):377-9. PubMed ID: 18809149
[No Abstract] [Full Text] [Related]
38. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial.
Spring S; Simon R; van der Loo B; Kovacevic T; Brockes C; Rousson V; Amann-Vesti B; Koppensteiner R
Thromb Haemost; 2008 Jan; 99(1):182-9. PubMed ID: 18217152
[TBL] [Abstract][Full Text] [Related]
39. Rosuvastatin: new preparation. Opt for statins with evidence of efficacy on clinical outcome.
Prescrire Int; 2004 Aug; 13(72):132-4. PubMed ID: 15532136
[TBL] [Abstract][Full Text] [Related]
40. A hydroxymethylglutaryl coenzyme A reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis.
Kishimoto N; Hayashi T; Sakuma I; Kano-Hayashi H; Tsunekawa T; Osawa M; Ina K; Iguchi A
Int J Cardiol; 2010 Nov; 145(1):21-6. PubMed ID: 19481279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
